The effectiveness of antioxidant therapy in aspirin resistance, diabetes population for prevention of thrombosis

被引:18
作者
Aboonabi, Anahita [1 ]
Singh, Indu [2 ]
机构
[1] Griffith Univ, Sch Med Sci, Gold Coast Campus, Gold Coast, Qld 4222, Australia
[2] Griffith Univ, Griffith Hlth Inst, Heart Fdn Res Ctr, Gold Coast Campus, Gold Coast, Qld 4222, Australia
关键词
Antioxidant; Aspirin; Aspirin resistance; Diabetes; Thrombosis; PROTEIN-KINASE-C; LOW-DOSE ASPIRIN; VITAMIN-E; NITRIC-OXIDE; PLATELET-FUNCTION; ENDOTHELIAL-CELLS; BLOOD-PRESSURE; HIGH-RISK; RESVERATROL; ACTIVATION;
D O I
10.1016/j.biopha.2016.06.044
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
100103 [病原生物学]; 100218 [急诊医学];
摘要
Thrombosis as the main complication of coronary heart disease (CHD) represents the primary cause of morbidity and mortality in patients with diabetes mellitus (DM). In the course of diabetes mellitus some coagulation abnormalities occur, that may result in a thrombogenic propensity. Aspirin (ASA) as a platelet-inhibiting agent through inactivation of Cyclooxygenase-1 (COX-1) is mostly used for the prevention and treatment of atherothrombotic disorders. ASA inhibits the COX-1 enzyme and therefore blocks platelet thromboxane A2 (TXA2) synthesis. However, some of the serious vascular events in high-risk vascular patients are attributable to a failure of ASA to suppress platelet aggregation. The consumption of antioxidant or antioxidant rich foods such as vitamin C, E, and polyphenols might impart anti-thrombotic and cardiovascular protective effects via their inhibition of platelet hyperactivation or aggregation similar to the action of aspirin. This review will discuss the risk of thrombosis in diabetes, what aspirin resistance means, and the effectiveness of antioxidant therapy in the prevention and possible treatment of atherothrombotic disorders. (C) 2016 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:277 / 282
页数:6
相关论文
共 73 条
[1]
Chemopreventive role of anthocyanins in atherosclerosis via activation of Nrf2-ARE as an indicator and modulator of redox [J].
Aboonabi, Anahita ;
Singh, Indu .
BIOMEDICINE & PHARMACOTHERAPY, 2015, 72 :30-36
[2]
Coagulation and atherothrombotic disease [J].
Ajjan, Ramzi ;
Grant, Peter J. .
ATHEROSCLEROSIS, 2006, 186 (02) :240-259
[3]
Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment [J].
Angiolillo, DJ ;
Fernandez-Ortiz, A ;
Bernardo, E ;
Ramírez, C ;
Sabaté, M ;
Jimenez-Quevedo, P ;
Hernández, R ;
Moreno, R ;
Escaned, J ;
Alfonso, F ;
Bañuelos, C ;
Costa, MA ;
Bass, TA ;
Macaya, C .
DIABETES, 2005, 54 (08) :2430-2435
[4]
Variability in Responsiveness to Oral Antiplatelet Therapy [J].
Angiolillo, Dominick J. .
AMERICAN JOURNAL OF CARDIOLOGY, 2009, 103 (3A) :27A-34A
[5]
Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71
[6]
THE ANTIOXIDANT ROLE OF VITAMIN-C [J].
BENDICH, A ;
MACHLIN, LJ ;
SCANDURRA, O ;
BURTON, GW ;
WAYNER, DDM .
ADVANCES IN FREE RADICAL BIOLOGY AND MEDICINE, 1986, 2 (02) :419-444
[7]
Bos M., 2010, METAB CARDIOVASC DIS, V20, P591
[8]
Flavonoid inhibition of platelet procoagulant activity and phosphoinositide synthesis [J].
Bucki, R ;
Pastore, JJ ;
Giraud, F ;
Sulpice, JC ;
Janmey, PA .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2003, 1 (08) :1820-1828
[9]
Endothelial dysfunction in cardiovascular diseases - The role of oxidant stress [J].
Cai, H ;
Harrison, DG .
CIRCULATION RESEARCH, 2000, 87 (10) :840-844
[10]
Dark chocolate inhibits platelet isoprostanes via NOX2 down-regulation in smokers [J].
Carnevale, R. ;
Loffredo, L. ;
Pignatelli, P. ;
Nocella, C. ;
Bartimoccia, S. ;
Di Santo, S. ;
Martino, F. ;
Catasca, E. ;
Perri, L. ;
Violi, F. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2012, 10 (01) :125-132